CAJ | 학술논문

目的探讨Luminal B-like乳腺癌临床病理特征以及St.Gallen共识治疗推荐的价值.方法以2010年1月至2012年12月间在北京大学第一医院乳腺疾病中心收治的浸润性乳腺癌患者为观察对象.依据2013年St.Gallen国际乳腺癌会议提出的“临床病理替代定义”的乳腺癌分型方法,将乳腺癌分为5个亚型,并进行统计学分析,探讨Luminal B-like型TNM分期、病理组织分级、Ki-67等临床病理特征的关系.结果 739例浸润性乳腺癌患者Luminal B-like 390例(52.8％),其中人表皮生长因子受体2(HER-2)阳性89例(22.8％);HER-2阴性301例(77.2％).依据St.Gallen共识推荐,仅7.3％的病例需要借助基因检测来决定是否需要化疗.结论从临床病理特征来看,Luminal B-like乳腺癌预后不佳,其中依据St.Gallen共识推荐化疗指征不确定的患者,可以从基因检测中获益.
목적 탐토Luminal B-like유선암림상병리특정이급St.Gallen공식치료추천적개치.방법 이2010년1월지2012년12월간재북경대학제일의원유선질병중심수치적침윤성유선암환자위관찰대상.의거2013년St.Gallen국제유선암회의제출적“림상병리체대정의”적유선암분형방법,장유선암분위5개아형,병진행통계학분석,탐토Luminal B-like형TNM분기、병리조직분급、Ki-67등림상병리특정적관계.결과 739례침윤성유선암환자Luminal B-like 390례(52.8％),기중인표피생장인자수체2(HER-2)양성89례(22.8％);HER-2음성301례(77.2％).의거St.Gallen공식추천,부7.3％적병례수요차조기인검측래결정시부수요화료.결론 종림상병리특정래간,Luminal B-like유선암예후불가,기중의거St.Gallen공식추천화료지정불학정적환자,가이종기인검측중획익.
Objective To explored the clinicopathological features of Luminal B-like breast cancer and analyze the value of St.Gallen consensus in its treatment.Methods The patients with invasive breast cancer treated at our hospital between January 2010 and December 2012 were recruited and divided into five subtypes according to the criteria of St.Gallen International Expert Consensus report 2013.And their TNM stages,pathological characteristics and Ki-67 status were analyzed for Luminal B-like subtype.Results The Luminal B-like subtype was found in 390 patients (52.8％),human epidermalgrowth factor receptor 2 (HER-2)positive in 89 patients (22.8％) and negative in 301 patients (77.2％).Only 7.3％ required chemotherapy based upon the result of gene detection.Conclusion Only those patients for whom the need of chemotherapy is to be determined shall really benefit from gene detection.